260 related articles for article (PubMed ID: 23088518)
21. γδ T cells in hepatocellular carcinoma patients present cytotoxic activity but are reduced in potency due to IL-2 and IL-21 pathways.
Jiang H; Yang Z; Song Z; Green M; Song H; Shao Q
Int Immunopharmacol; 2019 May; 70():167-173. PubMed ID: 30802679
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3.
Amann M; Brischwein K; Lutterbuese P; Parr L; Petersen L; Lorenczewski G; Krinner E; Bruckmeier S; Lippold S; Kischel R; Lutterbuese R; Kufer P; Baeuerle PA; Schlereth B
Cancer Res; 2008 Jan; 68(1):143-51. PubMed ID: 18172306
[TBL] [Abstract][Full Text] [Related]
23. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas.
Oberst MD; Fuhrmann S; Mulgrew K; Amann M; Cheng L; Lutterbuese P; Richman L; Coats S; Baeuerle PA; Hammond SA
MAbs; 2014; 6(6):1571-84. PubMed ID: 25484061
[TBL] [Abstract][Full Text] [Related]
24. Opsonization with a trifunctional bispecific (alphaCD3 x alphaEpCAM) antibody results in efficient lysis in vitro and in vivo of EpCAM positive tumor cells by cytotoxic T lymphocytes.
Schmitt M; Schmitt A; Reinhardt P; Thess B; Manfras B; Lindhofer H; Riechelmann H; Wiesneth M; Gronau S
Int J Oncol; 2004 Oct; 25(4):841-8. PubMed ID: 15375531
[TBL] [Abstract][Full Text] [Related]
25. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity.
Rischer M; Pscherer S; Duwe S; Vormoor J; Jürgens H; Rossig C
Br J Haematol; 2004 Aug; 126(4):583-92. PubMed ID: 15287953
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
[TBL] [Abstract][Full Text] [Related]
27. TIM-3 blockade combined with bispecific antibody MT110 enhances the anti-tumor effect of γδ T cells.
Guo Q; Zhao P; Zhang Z; Zhang J; Zhang Z; Hua Y; Han B; Li N; Zhao X; Hou L
Cancer Immunol Immunother; 2020 Dec; 69(12):2571-2587. PubMed ID: 32588076
[TBL] [Abstract][Full Text] [Related]
28. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
Liu Z; Guo B; Lopez RD
J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
[TBL] [Abstract][Full Text] [Related]
29. An EpCAM/CD3 bispecific antibody efficiently eliminates hepatocellular carcinoma cells with limited galectin-1 expression.
Zhang P; Shi B; Gao H; Jiang H; Kong J; Yan J; Pan X; Li K; Zhang P; Yao M; Yang S; Gu J; Wang H; Li Z
Cancer Immunol Immunother; 2014 Feb; 63(2):121-32. PubMed ID: 24177984
[TBL] [Abstract][Full Text] [Related]
30. Zoledronate Triggers Vδ2 T Cells to Destroy and Kill Spheroids of Colon Carcinoma: Quantitative Image Analysis of Three-Dimensional Cultures.
Varesano S; Zocchi MR; Poggi A
Front Immunol; 2018; 9():998. PubMed ID: 29867975
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy.
Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T
Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684
[TBL] [Abstract][Full Text] [Related]
32. Novel bispecific antibodies increase γδ T-cell cytotoxicity against pancreatic cancer cells.
Oberg HH; Peipp M; Kellner C; Sebens S; Krause S; Petrick D; Adam-Klages S; Röcken C; Becker T; Vogel I; Weisner D; Freitag-Wolf S; Gramatzki M; Kabelitz D; Wesch D
Cancer Res; 2014 Mar; 74(5):1349-60. PubMed ID: 24448235
[TBL] [Abstract][Full Text] [Related]
33. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K
Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372
[TBL] [Abstract][Full Text] [Related]
34. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3).
Riesenberg R; Buchner A; Pohla H; Lindhofer H
J Histochem Cytochem; 2001 Jul; 49(7):911-7. PubMed ID: 11410615
[TBL] [Abstract][Full Text] [Related]
35. Artesunate enhances γδ T-cell-mediated antitumor activity through augmenting γδ T-cell function and reversing immune escape of HepG2 cells.
Qian P; Zhang YW; Zhou ZH; Liu JQ; Yue SY; Guo XL; Sun LQ; Lv XT; Chen JQ
Immunopharmacol Immunotoxicol; 2018 Apr; 40(2):107-116. PubMed ID: 29405080
[TBL] [Abstract][Full Text] [Related]
36. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
37. [Hepatic stellate cells inhibit the proliferation and invasion of HepG2 hepatocellular carcinoma via activating γδ T cells].
Fan K; Liao R; Xie Y; Peng C; Du C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):870-874. PubMed ID: 28712391
[TBL] [Abstract][Full Text] [Related]
38. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells.
Nishio N; Fujita M; Tanaka Y; Maki H; Zhang R; Hirosawa T; Demachi-Okamura A; Uemura Y; Taguchi O; Takahashi Y; Kojima S; Kuzushima K
J Immunother; 2012 Oct; 35(8):598-606. PubMed ID: 22996365
[TBL] [Abstract][Full Text] [Related]
39. Aminobisphosphonate-pretreated dendritic cells trigger successful Vgamma9Vdelta2 T cell amplification for immunotherapy in advanced cancer patients.
Cabillic F; Toutirais O; Lavoué V; de La Pintière CT; Daniel P; Rioux-Leclerc N; Turlin B; Mönkkönen H; Mönkkönen J; Boudjema K; Catros V; Bouet-Toussaint F
Cancer Immunol Immunother; 2010 Nov; 59(11):1611-9. PubMed ID: 20582413
[TBL] [Abstract][Full Text] [Related]
40. EpCAM-high liver cancer stem cells resist natural killer cell-mediated cytotoxicity by upregulating CEACAM1.
Park DJ; Sung PS; Kim JH; Lee GW; Jang JW; Jung ES; Bae SH; Choi JY; Yoon SK
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
